Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-85,400
Closed -$1.81M 7911
2019
Q4
$1.81M Buy
85,400
+60,400
+242% +$1.34M ﹤0.01% 3658
2019
Q3
$574K Buy
+25,000
New +$570K ﹤0.01% 4448
2018
Q4
Sell
-4,800
Closed -$189K 7990
2018
Q3
$189K Buy
+4,800
New +$216K ﹤0.01% 5109
2017
Q4
Sell
-18,500
Closed -$1.55M 7812
2017
Q3
$1.55M Buy
+18,500
New +$1.31M ﹤0.01% 3341
2017
Q1
Sell
-4,200
Closed -$246K 7590
2016
Q4
$246K Buy
+4,200
New +$222K ﹤0.01% 4649

Other funds holding ADNT

UBS Group's ADNT Position: Q2 2026 in Review

UBS Group reduced its Adient (ADNT) stake by 12% in Q2 2026, selling an estimated $4.77M and leaving 1,703,353 shares worth $31.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2227.

UBS Group first reported a position in ADNT in Q4 2016 and has held it in 39 quarters since. The position peaked at $77.2M in Q1 2018. 313 funds tracked by Wall St. Rank hold ADNT as of Q2 2026.

  • UBS Group held 1,703,353 shares of Adient worth $31.3M as of Q2 2026.
  • UBS Group sold 223,256 Adient shares in Q2 2026, an estimated $4.77M.
  • Adient made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2227 holding.
  • UBS Group first reported a position in Adient in Q4 2016 and has held it in 39 quarters since.
  • UBS Group's Adient position peaked at $77.2M in Q1 2018.
  • 313 funds tracked by Wall St. Rank held Adient as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.